Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMINICA: Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Started Apr 2023; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05692180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692180.